Didemethylcurcumin

Didemethylcurcumin

SCHEMBL613666

O=C(/C=C/c1ccc(O)c(O)c1)CC(=O)/C=C/c1ccc(O)c(O)c1

nearest known ligand 0.77

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
IAPP P10997 4/20 0.77
APP P05067 6/20 0.69
BACE1 P56817 5/20 0.69
HSD17B10 Q99714 4/20 0.69
MAPT P10636 4/20 0.69
KDM4E B2RXH2 3/20 0.69
CYP2C9 P11712 3/20 0.69
TSHR P16473 3/20 0.69
AKR1B1 P15121 3/20 0.69
TTR P02766 2/20 0.69
MEN1 O00255 2/20 0.69
HDAC3 O15379 2/20 0.69
CA12 O43570 2/20 0.69
ALDH1A1 P00352 2/20 0.69
CA1 P00915 2/20 0.69
CA2 P00918 2/20 0.69
LMNA P02545 2/20 0.69
POLB P06746 2/20 0.69
CA3 P07451 2/20 0.69
CYP3A4 P08684 2/20 0.69

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Didemethylcurcumin SCHEMBL613667 1.00 IAPP (0.77) IAPPAPPBACE1HSD17B10MAPT
SCHEMBL29565303 0.93 AKR1B1 (0.76) IAPPAPPBACE1HSD17B10MAPT
SCHEMBL3671201 0.93 AKR1B1 (0.76) IAPPAPPBACE1HSD17B10MAPT
SCHEMBL3671196 0.93 AKR1B1 (0.76) IAPPAPPBACE1HSD17B10MAPT
SCHEMBL23242792 0.91 IAPP (0.66) IAPPAPPBACE1HSD17B10MAPT
SCHEMBL4005096 0.91 IAPP (0.71) IAPPAPPBACE1HSD17B10MAPT
SCHEMBL31297169 0.91 IAPP (0.66) IAPPAPPBACE1HSD17B10MAPT
SCHEMBL4005087 0.91 IAPP (0.71) IAPPAPPBACE1HSD17B10MAPT
SCHEMBL16881737 0.90 IAPP (0.69) IAPPAPPBACE1HSD17B10MAPT
SCHEMBL13810759 0.88 IAPP (0.67) IAPPAPPBACE1HSD17B10MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 94 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2023219526-A1 MULTITARGET ANTIVIRAL DIETARY SUPPLEMENT PROKIN MILAN (RS) 2023-11-16 WO claimed
WO-2021216954-A1 COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING VIRUS INFECTION ALPHA BETA HOLDINGS, LLC (US) 2021-10-28 WO claimed
EP-3455201-A1 PROCESS FOR THE MANUFACTURE OF HYDROXY-SUBSTITUTED AROMATIC COMPOUNDS BASF SE (DE) 2019-03-20 EP claimed
WO-2017194590-A1 PROCESS FOR THE MANUFACTURE OF HYDROXY-SUBSTITUTED AROMATIC COMPOUNDS BASF SE (DE) 2017-11-16 WO claimed
US-9233263-B2 Photoprotector and/or photoimmunoprotector compositions of the skin and their uses INDUSTRIAL FARMACEUTICA CANTABRIA, S.A. (ES) 2016-01-12 US claimed
US-20130102498-A1 COMPOSITIONS AND METHODS FOR DETECTING AMYLOID-BETA-DEGRADING ENZYME ACTIVITY ACADEMIA SINICA (TW) 2013-04-25 US claimed
US-20120039828-A1 Photoprotector and/or photoimmunoprotector compositions of the skin and their uses Industrial Framaceutica Cantabria, S.A. (ES) 2012-02-16 US claimed
WO-2023219526-A1 MULTITARGET ANTIVIRAL DIETARY SUPPLEMENT PROKIN MILAN (RS) 2023-11-16 WO disclosed
US-20220202962-A1 NITROXIDE CONTAINING AMYLOID BINDING AGENTS FOR IMAGING AND THERAPEUTIC USES THE REGENTS OF THE UNIVERSITY OF CALIFORNIA 2022-06-30 US disclosed
US-20220152001-A1 HUMAN THERAPEUTIC AGENTS ANKH LIFE SCIENCES LIMITED (IE) 2022-05-19 US disclosed
WO-2021216954-A1 COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING VIRUS INFECTION ALPHA BETA HOLDINGS, LLC (US) 2021-10-28 WO disclosed
US-10881748-B2 Nitroxide containing amyloid binding agents for imaging and therapeutic uses THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2021-01-05 US disclosed
US-20200383958-A1 HUMAN THERAPEUTIC AGENTS ANKH LIFE SCIENCES LIMITED (IE) 2020-12-10 US disclosed
WO-2010004579-A2 ORALLY ACTIVE CURCUMINOID COMPOUNDS LAILA PHARMACEUTICALS PVT. LTD. (IN) 2010-01-14 WO disclosed
US-20090004107-A1 BETA-AMYLOID AND NEUROFIBRILLARY TANGLE IMAGING AGENTS THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2009-01-01 US disclosed
WO-2008120220-A1 SYNERGISTIC ANTI-INFLAMMATORY AND ANTIOXIDANT DIETARY SUPPLEMENT COMPOSITIONS GOKARAJU GANGA RAJU (IN) 2008-10-09 WO disclosed
EP-1933625-A1 PROCESS FOR PRODUCING ENRICHED FRACTIONS OF TETRAHYDROXYCURCUMIN AND TETRAHYDROTETRAHYDROXY-CURCUMIN FROM THE EXTRACTS OF CURCUMA LONGA Gokaraju, Ganga, Raju (IN) 2008-06-25 EP disclosed
WO-2007043058-A1 PROCESS FOR PRODUCING ENRICHED FRACTIONS OF TETRAHYDROXYCURCUMIN AND TETRAHYDROTETRAHYDROXY-CURCUMIN FROM THE EXTRACTS OF CURCUMA LONGA GOKARAJU GANGA RAJU (IN) 2007-04-19 WO disclosed
WO-1994004139-A9 TREATMENT OF HUMAN VIRAL INFECTIONS 1994-04-28 WO disclosed
WO-1994004139-A1 TREATMENT OF HUMAN VIRAL INFECTIONS DANA FARBER CANCER INSTITUTE (US) 1994-03-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220202962-A1 NITROXIDE CONTAINING AMYLOID BINDING AGENTS FOR IMAGING AND THERAPEUTIC USES APP, APBA1, CRYAB IAPP 18/4885APP 1/4885BACE1 12/4885
US-10881748-B2 Nitroxide containing amyloid binding agents for imaging and therapeutic uses APP, APBA1, CRYAB IAPP 18/4885APP 1/4885BACE1 12/4885
US-20120039828-A1 Photoprotector and/or photoimmunoprotector compositions of the skin and their uses ME1, ME2, SI IAPP 4480/4885APP 3879/4885BACE1 2593/4885
US-20220152001-A1 HUMAN THERAPEUTIC AGENTS INMT, HNMT, HASPIN IAPP 1407/4885APP 1424/4885BACE1 1295/4885
US-20200383958-A1 HUMAN THERAPEUTIC AGENTS INMT, HNMT, HASPIN IAPP 1407/4885APP 1424/4885BACE1 1295/4885
US-20090004107-A1 BETA-AMYLOID AND NEUROFIBRILLARY TANGLE IMAGING AGENTS APP, PSEN1, PSEN2 IAPP 38/4885APP 1/4885BACE1 5/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.